By Sam Boughedda Oppenheimer analysts said in a note Friday that Sarepta Therapeutics Sarepta Therapeutics Inc (NASDAQ:SRPT) is "ripe" for a takeover. The analysts, who have an...
Robust pipeline of over 90 drugs, vaccinations make up 38% of revenues Reported its highest quarterly sales in history in Q2 2022 Recession-resistant due to COVID-19 vaccine...
Thematic exchange-traded funds (ETFs) aim to provide exposure to some of the hottest trends and industries in the stock market. Rather than looking for a winning stock, these...
Eli Lilly & Company LLY announced data from the third pivotal phase III study — ADhere — evaluating its investigational IL-13 inhibitor, lebrikizumab, in...
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (Duchenne), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) disorders. It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection. These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes more than 40 programs at various stages of discovery, pre-clinical and clinical development.